Prescription for Profit: Pharmaceutical-Biotech Industry's 2016 Outlook

SUGAR LAND--February 29, 2016--Researched by Annette Kreuger, Global VP Pharmaceutical-Biotech Group, Industrial Info Resources (Sugar Land, Texas)--With current economic reports going from bad to worse, the Pharmaceutical-Biotech Industry shines a strong ray of economic light. Despite the roller coaster rise and fall of the economic scene, the fact remains that a successful drug that the public either needs or desires, requires the facilities to develop, test, produce, package and distribute it. The epic rate of new drug approvals--paired with an ever expanding client base--is helping to fuel the growth in facilities across the globe. Industrial Info is tracking this growth with the launch of its global reporting in the Pharmaceutical-Biotech Industry. Within this article: Details on major developments in the Pharmaceutical-Biotech Industry for 2016, including Roche's Genentech, Novo Nordisk AS (NYSE:NVO), Biogen (NASDAQ:BIIB) and AstraZeneca (NYSE:AZN).